Operating CF
$12B
Capex
-$2.5B
Free Cash Flow
$9.48B
FCF Margin
+79.1%
Cash flow waterfall for Pfizer (PFE) — TTM through Q1 2026
Free cash flow: $9.48B
Cash flow breakdown for Pfizer (PFE) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Operating Cash Flow | $12B | $12B |
| Capital Expenditure | -$2.5B | $9.48B |
| Free Cash Flow | $9.48B | $9.48B |
| Acquisitions | -$13.2B | -$3.75B |
| Other Investing | $11.9B | $8.15B |
| Dividends Paid | -$9.78B | -$1.63B |
| Net Debt Change | $2.23B | $599M |
| Other Financing & FX | -$324M | $275M |
| Net Cash Increase | $275M | $275M |
- Operating Cash Flow$12B
- Capital Expenditure-$2.5B
- Free Cash Flow$9.48B
- Acquisitions-$13.2B
- Other Investing$11.9B
- Dividends Paid-$9.78B
- Net Debt Change$2.23B
- Other Financing & FX-$324M
- Net Cash Increase$275M
Want to see what drove the FCF change?Free Cash Flow Bridge
Frequently asked questions
Data & methodology
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Forecast & Valuation
Operations
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement
Capital Return
- Buybacks
- Dividend Profile6.93% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History6 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.